Velcade (Bortezomib, PS-341) and Rituximab in Relapsed/Refractory Mantle Cell and Follicular Non-Hodgkin's Lymphoma

NCT00201877 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

25

Enrollment

OTHER

Sponsor class

Conditions

Non-Hodgkin's Lymphoma
Mantle Cell Lymphoma

Interventions

DRUG: Velcade
DRUG: Rituximab

Sponsor

Ohio State University Comprehensive Cancer Center